10206-1 |
Physical findings |
Find |
Skin |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Skin Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10206-1 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Skin |
|
|
|
|
|
Dermatologic; Epidermis; Exam; Examination; Finding; Findings; H+P; H+P.PX; Integument; Narrative; P prime; Phys find; Point in time; Random; Report; Skn |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
102060-1 |
Perfluoroheptanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluoroheptanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102060-1 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFHpA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Perfluoroenanthic Acid; PFHpA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tridecafluoroheptanoic acid |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: changed to the anionic name per the Users' Guide section 2.1.2.13; |
0 |
102061-9 |
4,8-Dioxa-3H-perfluorononanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
4,8-Dioxa-3H-perfluorononanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102061-9 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
ADONA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
4,8-Dioxa-3H-perfluorononanoic acid; ADONA; DRUG/TOXICOLOGY; Drugs; DTXSID40881350; Level; Mass concentration; PFNA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: changed to anionic name per users' guide section 2.1.2.13); |
0 |
102062-7 |
Sum of branched perfluorooctanoate isomers |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Branched PFOA isomers [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102062-7 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
Sb-PFOA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; FC-143 component; Level; Mass concentration; Pentadecafluorooctanoic acid; PFOA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; Sb-PFOA; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
102063-5 |
n-Perfluorooctanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Linear PFOA Isomer [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102063-5 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
n-PFOA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; FC-143 component; Level; Mass concentration; n-PFOA; Pentadecafluorooctanoic acid; PFOA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: changed to the anionic name per the Users' Guide section 2.1.2.13; |
0 |
102064-3 |
Total perfluorohexanoic acid isomers |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Total perfluorohexanoic acid isomers [Mass/volume] in Serum or Plasma |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
Calculation: Sum of Branched PFOA Isomers and Linear PFOA Isomer results |
|
|
|
DRUG/TOX |
|
102064-3 |
|
|
|
|
Observation |
|
|
|
0 |
Total PFOA Isomers SerPl-mCnc |
|
|
|
N |
|
Acd; Acids; DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tot; Total PFOA Isomers; Totl |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: removed abbreviation for the name of the isomer; |
0 |
102065-0 |
Perfluorohexane sulfonate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorohexane sulfonate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102065-0 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFHxS SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFHxS; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the the anionic name ; |
0 |
102066-8 |
Perfluorononanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorononanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102066-8 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFNA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFNA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name; |
0 |
102067-6 |
Perfluoroheptane sulfonate |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Perfluoroheptane sulfonate [Mass/volume] in Serum or Plasma |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102067-6 |
|
|
|
|
Observation |
|
|
|
0 |
PFHpS SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFHpS; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name per the Users' Guide section 2.1.2.13; |
0 |
102068-4 |
Perfluoroundecanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluoroundecanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102068-4 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFUnDA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFUnDA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name; |
0 |
102069-2 |
Perfluorodecanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorodecanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102069-2 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFDA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; PFDA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: use the anionic name per the Users' Guide section 2.1.2.13; |
0 |
10207-9 |
Physical findings |
Find |
Thorax+Lungs |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Thorax and Lungs Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10207-9 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Thorax+Lungs |
|
|
|
|
|
Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Report; Thoracic |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
102070-0 |
Perfluoromethylheptane sulfonate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Branched PFOS Isomers [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102070-0 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
Sm-PFOS SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sm-PFOS; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name; |
0 |
102071-8 |
n-Perfluorooctane sulfonate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Linear PFOS Isomer [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102071-8 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
n-PFOS SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; n-PFOS; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: changed to anionic name per Users' Guide section 2.1.2.13 ; |
0 |
102072-6 |
2-N-Methyl-perfluorooctanesulfonamide acetate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
2-N-Methyl-perfluorooctanesulfonamide acetate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102072-6 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
Me-PFOSA-AcOH SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
Acetic acid; DRUG/TOXICOLOGY; Drugs; Ethanoate; Ethanoic acid; II; Level; Mass concentration; Me-PFOSA-AcOH; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: changed to anionic name per Users' Guide section 2.1.2.13; |
0 |
102073-4 |
Perfluorododecanoate |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorododecanoate [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
NAM |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102073-4 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFDoDA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Perfluorolauric acid; PFDoA; PFDoDA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Tricosafluorododecanoic acid |
2.77 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
Release 2.77: COMPONENT: updated to the anionic name per the Users' Guide section 2.1.2.13; |
0 |
102074-2 |
Perfluorooctane Sulfonamide |
MCnc |
Ser/Plas |
Pt |
Qn |
LC/MS/MS |
|
ACTIVE |
Perfluorooctane Sulfonamide [Mass/volume] in Serum or Plasma by LC/MS/MS |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
102074-2 |
|
LC/MS/MS |
|
|
Observation |
|
|
|
0 |
PFOSA SerPl LC/MS/MS-mCnc |
|
|
|
N |
|
C75; DRUG/TOXICOLOGY; Drugs; FOSA; Level; Mass concentration; Perfluorooctane sulfonamide; Perfluorooctanesulfonamide; PFOSA; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Sulf; Sulfa; Sulfas; Sulfonamides |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
102075-9 |
NASEM Summation Value |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
NASEM Summation Value [Mass/volume] in Serum or Plasma |
|
ADD |
DefinitionDescription |
|
|
ng/mL |
|
|
Calculation: Sum of Sb-PFOA, PFOA, PFHxS, PFNA, PFDA, Sm-PFOS, PFOS, PFUnDA, MeFOSAA results.Summation suggested by: National Academies of Sciences, Engineering, and Medicine |
|
|
|
DRUG/TOX |
|
102075-9 |
|
|
|
|
Both |
|
|
|
0 |
NASEM Summation Value SerPl-mCnc |
|
|
|
N |
|
DRUG/TOXICOLOGY; Drugs; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.75 |
2.75 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
102076-7 |
Insulin^3.5H post 75 g glucose PO |
ACnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Insulin [Units/volume] in Serum or Plasma --3.5 hours post 75 g glucose PO |
|
ADD |
DefinitionDescription |
|
|
uIU/mL |
|
|
|
|
|
|
CHAL |
|
102076-7 |
|
|
|
|
Both |
|
|
|
0 |
Insulin 3.5h p 75 g Glc PO SerPl-aCnc |
|
|
|
N |
|
3.5h p 75 g Glc PO; 75Gm; After; Arbitrary concentration; CHEMISTRY.CHALLENGE TESTING; Glu; Glu tol; Gluc; Glucose tolerance; Glucoseur; GTT; HUM; Humulin; IH7; Insul; Lente; NPH; p 75 g Glc PO; Pl; Plasma; Plsm; Point in time; PST; QNT; Quan; Quant; Quantitative; Random; Semilente; SerP; SerPl; SerPlas; Serum; Serum or plasma; Sliding; SR; Ultralente |
2.75 |
2.75 |
|
|
|
|
|
|
|
u[IU]/mL |
|
|
|
0 |
102078-3 |
Chimeric antigen receptor T-cell therapy panel |
- |
XXX |
Pt |
- |
|
|
ACTIVE |
CAR-T therapy panel - Specimen |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.DRUG/TOX |
|
102078-3 |
|
|
|
|
Order |
|
|
|
0 |
CAR-T panel Spec |
|
|
|
N |
|
Ag; CAR-T panel; DRUG/TOXICOLOGY; Drugs; Misc; Miscellaneous; Other; Pan; PANEL.DRUG & TOXICOLOGY; Panl; Pnl; Point in time; Random; Rec; Recept; Receptors; Recp; Recptr; Spec; T cell; T prime; To be specified in another part of the message; UCHL-1; Unspecified |
2.75 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |
102079-1 |
CAR-T dose |
NCnt |
^Patient |
Pt |
Qn |
|
|
ACTIVE |
CAR-T dose [#/mass] |
|
ADD |
DefinitionDescription |
|
|
10*6 |
|
|
|
|
|
|
DRUG/TOX |
|
102079-1 |
|
|
|
|
Both |
|
|
|
0 |
CAR-T dose Patient |
|
|
|
N |
|
Count/mass; DRUG/TOXICOLOGY; Drugs; Number content; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime |
2.75 |
2.75 |
|
|
|
|
|
|
|
10*6 |
|
|
|
0 |
10208-7 |
Physical findings |
Find |
Vessels |
Pt |
Nar |
Observed |
|
ACTIVE |
Physical findings of Vessels Narrative |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
H&P.PX |
|
10208-7 |
|
Observed |
|
|
|
|
|
|
0 |
Phys find Vesl |
|
|
|
|
|
Exam; Examination; Finding; Findings; H+P; H+P.PX; Narrative; P prime; Phys find; Point in time; Random; Report; Vesl; Vessels.XXX |
2.4 |
1.0i |
|
|
|
|
|
|
|
|
|
|
|
0 |
102080-9 |
CAR-T cell |
Type |
^BPU |
Pt |
Nom |
|
|
ACTIVE |
CAR-T cell [Type] in Blood product unit |
|
ADD |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
BLDBK |
|
102080-9 |
|
|
|
|
Observation |
|
|
|
0 |
CAR-T cell BPU |
|
|
|
N |
|
BLOOD BANK; Blood product unit; Blood Product Unit (Pack); Nominal; Point in time; Random; T prime; Typ; UCHL-1 |
2.75 |
2.75 |
|
|
|
|
|
|
|
|
|
|
|
0 |
102081-7 |
CAR-T cells.total |
Num |
^BPU |
Pt |
Qn |
|
|
ACTIVE |
CAR-T cells total [#] in Blood product unit |
|
ADD |
DefinitionDescription |
|
|
10*6 |
|
|
|
|
|
|
BLDBK |
|
102081-7 |
|
|
|
|
Observation |
|
|
|
0 |
CAR-T total BPU |
|
|
|
N |
|
BLOOD BANK; Blood product unit; Blood Product Unit (Pack); CAR-T total; Cell; Cellularity; Cnt; Count; Number; Point in time; QNT; Quan; Quant; Quantitative; Random; T prime; Tot; Totl |
2.75 |
2.75 |
|
|
|
|
|
|
|
10*6 |
|
|
|
0 |
102082-5 |
Alpha-1-Antitrypsin Proteotype panel |
- |
Ser/Plas |
Pt |
- |
|
|
ACTIVE |
Alpha-1-Antitrypsin Proteotype Panel - Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
PANEL.CHEM |
|
102082-5 |
|
|
|
|
Order |
|
|
|
0 |
A1AT Proteotype panel SerPl |
|
|
|
N |
|
A1; A1A; A1AT; A-1-AT; A1-AT; A1AT Proteotype panel; AAT; Alfa; Alpha-1-antitrypsin.total; Alpha-1-protease inhibitor; Alpha-1-proteinase inhibitor; Alpha-1-trypsin inhibitor; Chemistry; i; Pan; PANEL.CHEMISTRY; Panl; Pl; Plasma; Plsm; Pnl; Point in time; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.76 |
2.75 |
|
Panel |
|
|
|
|
|
|
|
|
|
0 |